Corneal therapeutic agent
AssigneeSinseiro Okamoto
InventorsSinseiro Okamoto, Sakae Amagaya, Kenji Sakamoto, Masanao Kanitani
Life of this patent
Estimating the term…
Loading patent…
AssigneeSinseiro Okamoto
InventorsSinseiro Okamoto, Sakae Amagaya, Kenji Sakamoto, Masanao Kanitani
Estimating the term…
A corneal therapeutic agent comprises at least one of a hexapeptide and a pharmacologically acceptable salt thereof, represented by formula (I) shown below, and a pharmacologically acceptable carrier, A-B-Pro-C-D-E (I) where A is L- or D-arginine or lysine whose N-terminal amino group is deaminated, alkylated or acylated; B is L- or D-arginine, lysine or hystidine; Pro is L- or D-proline; C is L- or D-tyrosine, tryptophane, or phenylalanine; D is L- or D-valine, isoleucine, or leucine having an amino group whose hydrogen atom may be substituted with an alkyl group having 1 to 4 carbon atoms; E is L- or D-valine, isoleucine or leucine having a C-terminal carboxylic group which is unsubstituted or substituted with --COOR, --CH.sub.2 OR or --CONHR, where R represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.
A method of preventing keratoleukoma comprising applying to the eye an amount of a hexapeptide effective to prevent keratoleukoma, wherein said hexapeptide is represented by the formula (I):
Dependencies are inferred from the claim text.